Biosyent Inc V.RX

Alternate Symbol(s): BIOYF

Healthcare

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.

TSXV:RX - Post by User

Biosyent Inc > Anyone care to guess what this is about?

<< Previous

Bullboard Posts

Next >>

Comment by theinvestor22on Jul 15, 2021 8:39pm

172 Views

Post# 33557195

RE:RE:Anyone care to guess what this is about?

Good find. Could be it...

lscfa wrote:
https://www.washington.edu/news/2016/09/07/hemaapp-screens-for-anemia-blood-conditions-without-needle-sticks/

theinvestor22 wrote:

BioSyent Signs Exclusive Technology Agreement

MISSISSAUGA, Ontario, July 13, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron deficiencies in Canada and BioSyent’s international markets.

“As a market leader in the treatment and prevention of iron deficiency and iron deficiency anemia with our FeraMAX® brand, we are familiar with the challenges that patients and their healthcare providers face with managing this condition,” said Ren Goehrum, President and CEO of BioSyent. “BioSyent is a leader and innovator in this therapeutic area and this initiative is another step towards better overall iron health for patients. We look forward to making this convenient technology available to Canadians and their healthcare providers in the 2nd half of 2021.”